Here at O4 Research, we are cognisant of the many challenges involved in this research area and that despite significant medical advances in the fields of allergy and respiratory medicine, there remains no cure for chronic conditions such as Asthma, COPD and Cystic Fibrosis. We also recognise the hugely competitive drug development environment associated with research in these indications and the associated pressure of Sponsors to optimise the clinical development strategy in order to help achieve more effective treatments.
Our team leverages both in-house cross functional team expertise combined with external medical expert input in order to collectively design study programmes with due consideration of the regulatory landscape, patient pathway through to market access and commercial pathway. From small Phase II studies extending to large real world and actual use studies which may focus on the clinical, cost effectiveness and safety of treatments or impact of ‘switching’, the team applies select methodologies and a tailored approach to each study. This approach helps achieve efficiencies, productivity and a consolidated study cycle period.